
## Andrzej Kacperek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3561002/publications.pdf Version: 2024-02-01



ANDRZEI KACDEREK

#	Article	IF	CITATIONS
1	Proton beam radiotherapy of choroidal melanoma: The Liverpool-Clatterbridge experience. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1405-1411.	0.4	196
2	Evaluation of Gafchromic® EBT3 films characteristics in therapy photon, electron and proton beams. Physica Medica, 2013, 29, 599-606.	0.4	170
3	Proton beam radiotherapy of iris melanoma. International Journal of Radiation Oncology Biology Physics, 2005, 63, 109-115.	0.4	108
4	Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma. British Journal of Ophthalmology, 1997, 81, 748-754.	2.1	86
5	Complex DNA Damage Induced by High Linear Energy Transfer Alpha-Particles and Protons Triggers a Specific Cellular DNA Damage Response. International Journal of Radiation Oncology Biology Physics, 2018, 100, 776-784.	0.4	86
6	Variations in the Processing of DNA Double-Strand Breaks Along 60-MeV Therapeutic Proton Beams. International Journal of Radiation Oncology Biology Physics, 2016, 95, 86-94.	0.4	74
7	Practice Patterns Analysis of Ocular Proton Therapy Centers: The International OPTIC Survey. International Journal of Radiation Oncology Biology Physics, 2016, 95, 336-343.	0.4	69
8	Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma. Eye, 2015, 29, 1194-1198.	1.1	63
9	A small-body portable graphite calorimeter for dosimetry in low-energy clinical proton beams. Physics in Medicine and Biology, 2004, 49, 3737-3749.	1.6	60
10	Proton beam radiotherapy of uveal melanoma. Saudi Journal of Ophthalmology, 2013, 27, 151-157.	0.3	57
11	The physics of Cerenkov light production during proton therapy. Physics in Medicine and Biology, 2014, 59, 7107-7123.	1.6	56
12	The 62 MeV proton beam for the treatment of ocular melanoma at Clatterbridge. British Journal of Radiology, 1993, 66, 907-914.	1.0	52
13	Ion recombination correction in the Clatterbridge Centre of Oncology clinical proton beam. Physics in Medicine and Biology, 2006, 51, 903-917.	1.6	45
14	Proton dosimetry intercomparison. Radiotherapy and Oncology, 1996, 41, 169-177.	0.3	41
15	Protontherapy of eye tumours in the UK: A review of treatment at Clatterbridge. Applied Radiation and Isotopes, 2009, 67, 378-386.	0.7	40
16	Whole anterior segment proton beam radiotherapy for diffuse iris melanoma. British Journal of Ophthalmology, 2013, 97, 471-474.	2.1	38
17	Profile of European proton and carbon ion therapy centers assessed by the EORTC facility questionnaire. Radiotherapy and Oncology, 2017, 124, 185-189.	0.3	33
18	A preliminary analysis of LET effects in the dosimetry of proton beams using PRESAGEâ,,¢ and optical CT. Applied Radiation and Isotopes, 2009, 67, 415-418.	0.7	30

ANDRZEJ KACPEREK

#	Article	IF	CITATIONS
19	Characterisation of Deubiquitylating Enzymes in the Cellular Response to High-LET Ionizing Radiation and Complex DNA Damage. International Journal of Radiation Oncology Biology Physics, 2019, 104, 656-665.	0.4	30
20	Characteristics of silicon and diamond detectors in a 60 MeV proton beam. Physics in Medicine and Biology, 2002, 47, N107-N112.	1.6	27
21	Fluence correction factors for graphite calorimetry in a low-energy clinical proton beam: I. Analytical and Monte Carlo simulations. Physics in Medicine and Biology, 2013, 58, 3481-3499.	1.6	22
22	Water equivalence of various materials for clinical proton dosimetry by experiment and Monte Carlo simulation. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2010, 619, 344-347.	0.7	19
23	Issues involved in the quantitative 3D imaging of proton doses using optical CT and chemical dosimeters. Physics in Medicine and Biology, 2015, 60, 709-726.	1.6	17
24	Monte carlo modelling of a clinical proton beam-line for the treatment of ocular tumours. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2006, 562, 1005-1008.	0.7	16
25	Experimental and Monte Carlo studies of fluence corrections for graphite calorimetry in low―and highâ€energy clinical proton beams. Medical Physics, 2016, 43, 4122-4132.	1.6	16
26	True-3D scans using PRESAGETMand Optical-CT: A case study in proton therapy. Journal of Physics: Conference Series, 2006, 56, 231-234.	0.3	15
27	Monte Carlo simulation and polymer gel dosimetry of 60MeV clinical proton beams for the treatment of ocular tumours. Applied Radiation and Isotopes, 2009, 67, 402-405.	0.7	15
28	Iridocyclectomy for neovascular glaucoma caused by proton-beam radiotherapy of pigmented ciliary adenocarcinoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 1499-1501.	1.0	14
29	Ocular Proton Therapy Centers. Biological and Medical Physics Series, 2012, , 149-177.	0.3	13
30	Recurrence of iris melanoma after proton beam therapy. British Journal of Ophthalmology, 2014, 98, 484-487.	2.1	13
31	Transpalpebral proton beam radiotherapy of choroidal melanoma. British Journal of Ophthalmology, 2015, 99, 232-235.	2.1	13
32	The application of a pulsed fast neutron beam to partial body in vivo activation analysis of minerals and trace elements. Journal of Radioanalytical and Nuclear Chemistry, 1990, 140, 141-151.	0.7	12
33	Response of synthetic diamond detectors in proton, carbon, and oxygen ion beams. Medical Physics, 2017, 44, 5445-5449.	1.6	12
34	Local tumour control and radiation side effects for fractionated stereotactic photon beam radiotherapy compared to proton beam radiotherapy in uveal melanoma. Radiotherapy and Oncology, 2021, 157, 219-224.	0.3	12
35	An approach to 3D dose mapping using gafchromic® film. Radiation Protection Dosimetry, 2005, 115, 616-622.	0.4	11
36	Practice Considerations for Proton Beam Radiation Therapy of Uveal Melanoma During the Coronavirus Disease Pandemic: Particle Therapy Co-Operative Group Ocular Experience. Advances in Radiation Oncology, 2020, 5, 682-686.	0.6	11

ANDRZEJ KACPEREK

#	Article	IF	CITATIONS
37	Water equivalence of some plastic-water phantom materials for clinical proton beam dosimetry. Applied Radiation and Isotopes, 2012, 70, 1052-1057.	0.7	10
38	Effects of plaque brachytherapy and proton beam radiotherapy on prognostic testing: a comparison of uveal melanoma genotyped by microsatellite analysis. British Journal of Ophthalmology, 2020, 104, 1462-1466.	2.1	10
39	A correction method for diamond detector signal dependence with proton energy. Medical Physics, 2002, 29, 669-675.	1.6	9
40	A high-resolution anthropomorphic voxel-based tomographic phantom for proton therapy of the eye. Physics in Medicine and Biology, 2007, 52, N51-N59.	1.6	8
41	Dose verification by activation in vivo following proton beam eye radiotherapy. Journal of Radioanalytical and Nuclear Chemistry, 2007, 271, 731-740.	0.7	8
42	An investigation of the response of the radiochromic dosimeter PRESAGE <sup>TM</sup> to irradiation by 62 MeV protons. Journal of Physics: Conference Series, 2010, 250, 012034.	0.3	7
43	Modelling concepts of proton eye radiotherapy. Physiological Measurement, 2001, 22, 611-623.	1.2	6
44	USP9X Is Required to Maintain Cell Survival in Response to High-LET Radiation. Frontiers in Oncology, 2021, 11, 671431.	1.3	6
45	A system for the determination of silicon in the human lung using neutrons from A 2MV Van de Graaff generator. Journal of Radioanalytical and Nuclear Chemistry, 1987, 114, 165-172.	0.7	4
46	The quenching effect in PRESAGE® dosimetry of proton beams: Is an empirical correction feasible?. Journal of Physics: Conference Series, 2015, 573, 012043.	0.3	4
47	Proton and particle radiotherapy — a report on the Franco–British seminar on the future of cancer treatment and imaging using new physics-based technologies. British Journal of Radiology, 2009, 82, 183-189.	1.0	3
48	Preliminary characterization of PRESAGE <sup>®</sup> for 3D dosimetry of 62 MeV proton beam. Journal of Physics: Conference Series, 2013, 444, 012058.	0.3	3
49	Range verification for eye proton therapy based on proton-induced x-ray emissions from implanted metal markers. Physics in Medicine and Biology, 2014, 59, 2623-2638.	1.6	3
50	The influence of physical wedges on penumbra and in-field dose uniformity in ocular proton beams. Physica Medica, 2016, 32, 612-617.	0.4	3
51	Proton beam radiotherapy (PBR) for the treatment of retinal capillary haemangioblastoma stabilises tumour progression but with poor visual outcomes. Eye, 2019, 33, 1188-1190.	1.1	3
52	The measurement of silicon in a lung phantom-a comparison of two nuclear reactions for in vivo activation analysis. Physics in Medicine and Biology, 1993, 38, 689-698.	1.6	2
53	Beam characterisation studies of the 62ÂMeV proton therapy beamline at the Clatterbridge Cancer Centre. Physica Medica, 2020, 77, 108-120.	0.4	2
54	Modulation of fast neutron pulses for dose reduction during in vivo activation analysis: application to the measurement of magnesium in a bone phantom. Physics in Medicine and Biology, 1987, 32, 1649-1653.	1.6	1

#	Article	IF	CITATIONS
55	Medical benefits of nuclear physics. Physics World, 2003, 16, 19-20.	0.0	Ο
56	Determination of depth of a radionuclide source in a tissue equivalent phantom. Journal of Radioanalytical and Nuclear Chemistry, 2013, 296, 807-810.	0.7	0
57	Cerenkov optical emissions in particle radiotherapy. , 2014, , .		0